abstract |
The present invention relates to novel heterocyclic compounds of general formula (I), pharmaceutically acceptable salts thereof, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The present invention further relates to methods for the preparation of the compounds of the invention, pharmaceutical compositions containing the compounds, and those as compounds of the invention belonging to the family of NOD-like receptor family (NLR) protein NLRP3 modulators. Regarding the use of. The invention therefore relates to novel NLRP3 modulators, as well as novel inhibitor compounds in the treatment of diseases or conditions involving interleukin 1β activity. |